Background. Current pharmacological management for patients with chronic obstructive pulmonary disease (COPD) focuses on inhaled long-acting bronchodilators, which are considered as the recommended first-line treatment option for such patients.Methods. A prospective study was conducted in 70 patients with moderate to severe COPD. Thirty-five patients (Group A) were administered daily glycopyrronium bromide (50μg) and 35 (Group B) received tiotropium bromide (18μg). Patients were assessed for forced expiratory volume in one second (FEV 1 ) score, COPD assessment scale (CAT), modified Medical Research Council (mMRC) scale, body-mass index, airflow obstruction, dyspnoea and exercise (BODE) index for COPD survival for two consecutive follow-ups after every three months of drug use. Results.Group A showed a significant improvement with respect to different evaluation methods compared to group B. Significant results were observed for group A parameters were mMRC (0.0001), CAT (0.01), BODE (0.0001) and FEV 1 (0.03). Conclusions.In patients with moderate to severe COPD, glycopyrronium bromide (50μg) once daily is found to be more beneficial than tiotropium bromide (18μg).